June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
An evaluation of OCT and visual field measures as endpoints of glaucoma progression
Author Affiliations & Notes
  • Emmanouil (Manos) Tsamis
    Psychology, Columbia University, New York, New York, United States
  • C. Gustavo De Moraes
    Ophthalmology, Columbia University, New York, New York, United States
  • George A Cioffi
    Ophthalmology, Columbia University, New York, New York, United States
  • Jeffrey M Liebmann
    Ophthalmology, Columbia University, New York, New York, United States
  • Donald C Hood
    Psychology, Columbia University, New York, New York, United States
    Ophthalmology, Columbia University, New York, New York, United States
  • Footnotes
    Commercial Relationships   Emmanouil (Manos) Tsamis None; C. Gustavo De Moraes Carl Zeiss, Novartis, Perfuse Therapeutics, Thea Pharma, Code C (Consultant/Contractor), Ora Clinical, Code E (Employment); George Cioffi None; Jeffrey Liebmann AdvanceSight, Alcon Inc., Allergan Inc., Carl Zeiss Meditech, Genentech Inc., Johnson and Johnson Inc., ONL Therapeutics Inc., Thea Inc., Code C (Consultant/Contractor); Donald Hood Novartis, Heidelberg Eng., Topcon Inc., Code F (Financial Support), Heidelberg Eng., Topcon Inc., Code R (Recipient)
  • Footnotes
    Support  NIH Grant K99-EY032182, Unrestricted Grant by Research to Prevent Blindness
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4310. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Emmanouil (Manos) Tsamis, C. Gustavo De Moraes, George A Cioffi, Jeffrey M Liebmann, Donald C Hood; An evaluation of OCT and visual field measures as endpoints of glaucoma progression. Invest. Ophthalmol. Vis. Sci. 2023;64(8):4310.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate optical coherence tomography (OCT) and visual field (VF) measures (metrics) as clinical endpoints for progression of early glaucomatous damage in eyes with confirmed progression.

Methods : OCT scans of the disc and the macula and 24-2 and 10-2 VFs were obtained from 87 eyes [33 healthy controls (HC), 54 patients with 24-2 mean deviation (MD) better than -6dB] with at least 4 tests (mean: 7.1±1.5) and at least 1 year between baseline (first) and last follow-up test (mean: 3.4yrs; range: 1.2 – 5.34yrs). 10 of the 54 patient eyes were labelled as ‘Definite Progressors’ (DP), based on qualitative assessment of structural and functional series of tests.1 Metrics of the circumpapillary RNFL (cpRNFL) and the macular ganglion cell layer (GCL) thickness were extracted from the OCT scans and the MD and visual field index (VFI) from the 24-2 and 10-2 VFs. Ordinary linear regression analyses over time were performed for all metrics and eyes. For each sector, negative slopes less than a criterion value based on the HC eyes and a 95% specificity were considered indicative of progression. A Kaplan-Meier method of survival analysis was used to identify the time to progression.

Results : Progression in all 10 DP eyes was detected by at least one OCT or VF metric within 2.2 years of follow-up. However, the VF metrics alone detected only 7 of the 10 DP eyes, while the OCT metrics detected all 10. At 1.5 yrs, the superior MD of the 24-2 was the best VF metric detecting 30% of the DP eyes, while five OCT metrics, 3 from GCL and 2 from cpRNFL, exceeded a detection rate of 30%, ranging between 40-60% (Table 1). The cpRNFL temporal inferior (TI) was the fastest in detecting progression in 7 eyes. For the eye in Fig. 1, for example, the cpRNFL TI and temporal superior (TS), as well as GCL TI, were the fastest, while none of the VF metrics detected progression. For the remaining 3 eyes, the GCL inferior (I) metric was the fastest in 2, and the cpRNFL TS in 1. The global (G) metrics of cpRNFL and GCL were fastest in 3 eyes; however, it was always in conjunction with another sectoral metric.

Conclusions : While it was possible to detect progression in eyes with confirmed progression within 2.2 yrs, no one metric identified all eyes within that time period. The a priori selection of a sectoral metric, based on glaucomatous damage at baseline, might enhance the ability to detect progression.
1.Hood et al., Ophthal Glau, 2022.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×